Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL

Next Previous
Trial Profile

A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Methotrexate; Pegfilgrastim; Prednisone; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IRiC

Most Recent Events

  • 15 Jun 2023 Results assessing the safety and efficacy of ibrutinib-R-mini-CHOP in very elderly patients with newly diagnosed diffuse large B cell lymphoma, presented at the 28th Congress of the European Haematology Association.
  • 02 Jun 2023 Status changed from active, no longer recruiting to completed.
  • 14 Dec 2021 Primary endpoint (efficacy) has not been met, as per results presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top